RybeccaSmith

$CRVS SID Data for Cohort 4 Atopic Dermatitis Summary: Very strong and continues to develop ITK inhibition story as novel immune rebalancing “The data supports the effects of soquelitinib on multiple T cell properties including cytokine production, inflammatory cell function and the induction of persistent Tregs. The data also provides support for the findings of the lack of disease rebound observed in treated patients.” "The data also supports the potential for soquelitinib to be a novel treatment for a range of autoimmune and inflammatory diseases based on a rebalancing of immunity" - Cohorts 1-3 EASI-75 keeps RISING every 30 days over 3 months after treatment (~38% to >50% over 90 days) - Tregs higher (+150%) and stay elevated for 30 days - #Soquelitinib lowers #JAK1 + #STAT6 - SQL continues to lower IL-4, IL-5, IL-13, TARC even after drug stopped => durable benefit - SQL lowers RORγT, key transcription factor for #Th17, suggesting broad range benefit beyond just #Th2 diseases and opens door wide for SQL in more than just AD and asthma, but also HS, psoriasis, IBD, etc Soquelitinib is first-in-class selective oral ITK inhibitor w/ evidence accumulating it is only-in-class immune-reprogramming leading to drug-free remission profile investor.corvuspharma.com/news-releases/…